Abstract
Leishmaniasis is a diverse group of neglected diseases caused by protozoan parasite of genus Leishmania and transmitted by the bite of a female phlebotomine sand fly. These diseases stand as a major health problem worldwide, especially in their visceral form. Despite innumerable studies on leishmaniasis, many questions are still unanswered. One of the main challenges is the presence of different Leishmania species and various clinical manifestations, complicating the therapeutic approach. There are many available antileishmanial agents, but the drug of choice is still out of reach, since almost all available drugs share several limitations and many of them are expensive with severe side effects or have a markedly reduced effectiveness. Immunosuppressed patients should also be given a special attention which represents an additional challenge. In the meantime, the combination of local and parenteral therapies with existing drugs remain a priority to improve the efficacy and to shorten the duration of the treatment. This review was undertaken to highlight the chemotherapeutic strategies, their mechanisms of action and main limitations.
Keywords: Leishmaniasis, treatment, chemotherapy, combination therapy, immunomodulation.
Current Pharmaceutical Design
Title:Treatment of Leishmaniasis: A Review and Assessment of Recent Research
Volume: 21 Issue: 17
Author(s): Ehab Kotb Elmahallawy and Ahmad Agil
Affiliation:
Keywords: Leishmaniasis, treatment, chemotherapy, combination therapy, immunomodulation.
Abstract: Leishmaniasis is a diverse group of neglected diseases caused by protozoan parasite of genus Leishmania and transmitted by the bite of a female phlebotomine sand fly. These diseases stand as a major health problem worldwide, especially in their visceral form. Despite innumerable studies on leishmaniasis, many questions are still unanswered. One of the main challenges is the presence of different Leishmania species and various clinical manifestations, complicating the therapeutic approach. There are many available antileishmanial agents, but the drug of choice is still out of reach, since almost all available drugs share several limitations and many of them are expensive with severe side effects or have a markedly reduced effectiveness. Immunosuppressed patients should also be given a special attention which represents an additional challenge. In the meantime, the combination of local and parenteral therapies with existing drugs remain a priority to improve the efficacy and to shorten the duration of the treatment. This review was undertaken to highlight the chemotherapeutic strategies, their mechanisms of action and main limitations.
Export Options
About this article
Cite this article as:
Elmahallawy Ehab Kotb and Agil Ahmad, Treatment of Leishmaniasis: A Review and Assessment of Recent Research, Current Pharmaceutical Design 2015; 21 (17) . https://dx.doi.org/10.2174/1381612821666141231163053
DOI https://dx.doi.org/10.2174/1381612821666141231163053 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dietary Phytochemicals in Chemoprevention of Cancer: An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Metabonomics: Its Potential as a Tool in Toxicology for Safety Assessment and Data Integration
Current Drug Metabolism Epidemiology of Vitamin D and Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Studies on the Pathophysiology and Genetic Basis of Migraine
Current Genomics Hypomethylation and Activation of Syncytin-1 Gene in Endometriotic Tissue
Current Pharmaceutical Design Somatic Genomic Variations in Extra-Embryonic Tissues
Current Genomics Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry New Uses of Melatonin as a Drug; A Review
Current Medicinal Chemistry Pharmacokinetics and Disposition of Nanomedicine Using Biodegradable PEG/PCL Polymers as Drug Carriers
Current Drug Metabolism Concentrations of Cd, Cu, Pb and Zn in Blood Serum of Cancer Patients and Comparison with Healthy Person by Atomic Absorption Spectrometry
Current Analytical Chemistry The Emergence of Non-coding RNAs as Versatile and Efficient Therapeutic Tools
Current Gene Therapy Corticotropin Releasing Factor (CRF) Peptide Family and their Receptors: Divergent Actions Influencing Human Physiology
Current Genomics Folic Acid Conjugated Chitosan Nanoparticles for Tumor Targeting of Therapeutic and Imaging Agents
Pharmaceutical Nanotechnology The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Curcumin Therapeutic Modulation of the Wnt Signaling Pathway
Current Pharmaceutical Biotechnology